Enter Your Email Address to Receive a
Copy of MedicExhange Member Demograhpics

iCAD, Inc. will release financial results for the third quarter and nine months ended September 30, 2009, following the close of the market on Wednesday, October 28, 2009.

iCAD , Inc. (NASDAQ: ICAD), an industry-leading provider of advanced image analysis and workflow solutions for the early identification of cancer, announced that the Company will release financial results for the third quarter and nine months ended September 30, 2009, following the close of the market on Wednesday, October 28, 2009.

Ken Ferry, President and Chief Executive Officer, and Darlene Deptula-Hicks, Executive Vice President and Chief Financial Officer, will host a conference call for investors beginning at 10:00 a.m. Eastern Time on Thursday, October 29, 2009 to discuss third quarter and nine months 2009 financial results and to answer questions.

Shareholders and other interested parties may participate in the conference call by dialing 866-510-0712 (domestic) or 617-597-5380 (international) and entering passcode 16114889 a few minutes before 10:00 a.m. ET on Thursday, October 29, 2009. The call will also be broadcast live on the Internet at www.streetevents.com, www.fulldisclosure.com and www.icadmed.com.

A replay of the conference call will be accessible two hours after its completion through November 5, 2009 by dialing 888-286-8010 (domestic) or 617-801-6888 (international) and entering passcode 58984549. The call will also be archived for 90 days at www.streetevents.com, www.fulldisclosure.com and www.icadmed.com.

About iCAD , Inc.
iCAD , Inc. is an industry-leading provider of advanced image analysis and workflow solutions that enable healthcare professionals to better serve patients by identifying pathologies and pinpointing cancer earlier. iCAD offers a comprehensive range of high-performance, upgradeable Computer-Aided Detection (CAD) systems and workflow solutions for mammography (film-based, digital radiography (DR) and computed radiography (CR)), Magnetic Resonance Imaging (MRI), and Computed Tomography (CT). Since receiving FDA approval for the Company’s first breast cancer detection product in 2002, over 3,200 iCAD systems have been placed in healthcare practices worldwide. iCAD’s solutions aid in the early detection of the most prevalent cancers including breast, prostate and in the future, colon and lung cancer. For more information, call (877) iCADnow or visit www.icadmed.com.

Source: iCAD , Inc.

You can discuss about iCAD , Inc. and its products & services in the iCAD , Inc. Company User Group